The
antihypertensive effects of
NIP-121, a novel
potassium channel opener, were examined in comparison with
cromakalim and its active enantiomer,
lemakalim. In experiments by direct blood pressure measurements, orally administered
NIP-121 dose-relatedly decreased arterial blood pressure in conscious spontaneously hypertensive rats (SHRs), and the ED20 values (the doses to produce 20% decrease of the mean blood pressure) of
NIP-121 and
cromakalim were 0.010 and 0.11 mg/kg, respectively,
NIP-121 thus being about ten times more potent than
cromakalim. The duration of the hypotensive effect by
NIP-121 was longer than that by
cromakalim. The hypotensive effect of
NIP-121 was stronger in SHRs than in normotensive rats. All three drugs showed
tachycardia that was antagonized by a beta-blocker,
propranolol. Intravenously administered
NIP-121 also showed a more potent hypotensive action with longer duration than
cromakalim in conscious SHRs. The ED20 values for
hypotension by
NIP-121,
cromakalim, and
lemakalim were 0.017, 0.040, and 0.016 mg/kg, respectively. The intravenous hypotensive potency of
NIP-121 but not
cromakalim was similar to that of p.o. administration. The repeated treatments with
NIP-121 (0.025, 0.05, and 0.1 mg/kg p.o. once a day) for 15 days did not modify the degree of the hypotensive action. In the anesthetized SHRs, pretreatment with
glibenclamide but not other antagonists (
atropine,
propranolol,
diphenhydramine +
cimetidine, or
indomethacin) suppressed the decrease in blood pressure induced by
NIP-121.(ABSTRACT TRUNCATED AT 250 WORDS)